Archive - December 2017
FDA Approves Steglatro (ertugliflozin) for Type 2 Diabetes
FDA Clears Stereotactic Radiotherapy System for Use in Treating Breast Cancer
FDA Updates the Label of Tasigna to Reflect that Certain Patients with a Type of Leukemia May be Eligible to Stop Treatment After Sustained Response
Furthering Your R&D Budget While Simultaneously Boosting Innovation
FDA Approves Giapreza (angiotensin II) to Treat Dangerously Low Blood Pressure
Get Ready for mHealth to Revolutionize the Device Market
How Prepared Is Your State For A Public Health Emergency?
Four More Research Organizations Accredited by the AAHRPP